Acid-C1-PEG5-Boc
CAS No. 2304558-22-1
Acid-C1-PEG5-Boc( —— )
Catalog No. M26877 CAS No. 2304558-22-1
Acid-C1-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 29 | In Stock |
|
| 25MG | 49 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 123 | In Stock |
|
| 200MG | 179 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAcid-C1-PEG5-Boc
-
NoteResearch use only, not for human use.
-
Brief DescriptionAcid-C1-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
DescriptionAcid-C1-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLOX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2304558-22-1
-
Formula Weight380.434
-
Molecular FormulaC17H32O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)(C)OC(=O)CCOCCOCCOCCOCCOCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PTGR2-IN-22
PTGR2-IN-22 is a potent inhibito of PTGR2r(IC50 : 0.7 μM). It increases 15-keto-PGE2-dependent PPARγ transcriptional activity in PTGR2-transfected HEK293T cells.
-
S1PR1 modulator 1
S1PR1 modulator 1 is a selective inhibitor of S1PR1 with a pIC50 of 7.6.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
Cart
sales@molnova.com